Compositions Against Cancer Antigen LIV-1 and Uses Thereof

Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

1 . A monoclonal antibody that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2, wherein the antibody is selected from the group consisting of antibodies designated as 1.1F10, 1.7A4, BR2-10b, BR2-11a, BR2-13a, BR2-14a, BR2-15a, BR2-16a, BR2-17a, BR2-18a, 8R2-19a, BR2-20a, BR2-21a, BR2-22a, BR2-23a, BR2-24a, and BR2-25a, or a chimeric or humanized form thereof. 
     
     
         2 . The antibody of  claim 1 , which is a chimeric or humanized antibody. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody is BR2-14a as produced by the hybridoma having ATCC Accession No. PTA-5705. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody is BR2-19a as produced by the hybridoma having ATCC Accession No. PTA-5706. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody is BR2-23a as produced by the hybridoma having ATCC Accession No. PTA-5707. 
     
     
         6 . The antibody of  claim 2 , wherein the antibody has heavy chain variable region complementarity determining regions (CDRs) having the amino acid sequences of the heavy chain variable region CDRs of SEQ ID NO:3 and has light chain variable region CDRs having the amino acid sequences of the light chain variable region CDRs of SEQ ID NO:4. 
     
     
         7 . The antibody of  claim 6 , wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:3 and a light chain variable region having the amino acid sequence of SEQ ID NO:4. 
     
     
         8 . The antibody of  claim 2 , wherein the antibody is an antibody fragment. 
     
     
         9 . The antibody of  claims 2 , wherein the antibody is conjugated to an effector component. 
     
     
         10 . The antibody of  claim 9 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical. 
     
     
         11 . The antibody of  claim 10 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         12 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of  claim 2 . 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the antibody is an antibody fragment. 
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein the antibody is conjugated to an effector component comprising a radioisotope or a cytotoxic chemical. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         16 . A method of treating an individual with prostate or breast cancer, wherein the method comprises administering a therapeutically effective dose of the antibody of  claim 2  to the individual. 
     
     
         17 . The method of  claim 16 , wherein the antibody is a chimeric antibody. 
     
     
         18 . The method of  claim 16 , wherein the antibody is a humanized antibody. 
     
     
         19 . The method of  claim 16 , wherein the antibody is an antibody fragment. 
     
     
         20 . The method of  claim 16 , wherein the antibody is conjugated to an effector component comprising a radioisotope or a cytotoxic chemical. 
     
     
         21 . The method of  claim 20 , wherein the cytotoxic chemical is auristatin-E or MMAE. 
     
     
         22 . A hybridoma having ATCC Accession No. PTA-5705. 
     
     
         23 . A hybridoma having ATCC Accession No. PTA-5706. 
     
     
         24 . A hybridoma having ATCC Accession No. PTA-5707.